STOCK TITAN

[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity

BIO-RAD LABORATORIES, INC.

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BIO-RAD LABORATORIES, INC. (symbol: BIO) is the issuer of record for a Form 4 filing submitted to the SEC.

Positive

  • None.

Negative

  • None.
Insider DiVincenzo Jonathan P.
Role President & COO
Type Security Shares Price Value
Exercise Restricted Stock Units F2, F4 1,712 $0.00 $0.00
Exercise Bio-Rad A Common Stock F1 1,712 $0.00 $0.00
Exercise Price or Tax Liability Bio-Rad A Common Stock 668 $386.11 $258K
Grant/Award Restricted Stock Units F2, F3 6,326 $0.00 $0.00
Holdings After Transaction: Restricted Stock Units — 11,464 contracts (Direct); Bio-Rad A Common Stock — 1,963 shares (Direct)
Footnotes (4)
  1. F1. Shares of Class A common stock acquired on the vesting of restricted stock units.
  2. F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  3. F3. The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter.
  4. F4. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DiVincenzo Jonathan P.

(Last)(First)(Middle)
C/O BIO-RAD LABORATORIES, INC.
1000 ALFRED NOBEL DRIVE

(Street)
HERCULES CALIFORNIA 94547

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President & COO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Bio-Rad A Common Stock09/05/2026M1,712(1)A$02,631D
Bio-Rad A Common Stock09/05/2026F668D$386.111,963D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$0(2)09/04/2026A6,326 (3) (3)Bio-Rad A Common Stock6,326$06,326D
Restricted Stock Units$0(2)09/05/2026M1,712 (4) (4)Bio-Rad A Common Stock1,712$05,138D
Explanation of Responses:
1. Shares of Class A common stock acquired on the vesting of restricted stock units.
2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
3. The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter.
4. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Remarks:
/s/ Jonathan P. DiVincenzo09/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading